medRxiv preprint doi: https://doi.org/10.1101/2025.02.05.25321745; this version posted February 8, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

# perpetuity. It is made available under a CC-BY-NC 4.0 International license .

### Exploring multidrug resistance patterns in community-1 acquired E. coli urinary tract infections with machine 2 learning 3

- 4
- Authors: Elise HODBERT <sup>1,2</sup>, Olivier LEMENAND <sup>3,4</sup>, Sonia THIBAUT <sup>3,4</sup>, Thomas 5
- COEFFIC <sup>3,4</sup>, David BOUTOILLE <sup>4,5</sup>, Stephane CORVEC <sup>6,7</sup>, Gabriel BIRGAND <sup>1,3,4\*</sup>, 6
- Laura TEMIME <sup>1,8\*</sup> on behalf of the French Clinical Laboratories Nationwide 7
- 8 Network+
- 9
- 10 <sup>1</sup> Cibles et médicaments des infections et de l'immunité, IICiMed, Nantes Université, Nantes, France 11
- 12 <sup>2</sup> Laboratoire Modélisation, Epidémiologie et Surveillance des Risques Sanitaires
- (MESuRS), Conservatoire National des Arts et Métiers, Paris, France 13
- <sup>3</sup> Centre d'Appui à la Prévention des Infections Associées aux Soins des Pays de la 14
- Loire, Centre Hospitalier Universitaire (CHU) Le Tourville, Nantes, France 15
- 16 <sup>4</sup> French National Surveillance System of Antimicrobial Resistance in Primary Care 17 and Nursing Homes, PRIMO, CHU - Le Tourville, Nantes, France
- 18 <sup>5</sup> Department of Infectious Diseases, University Hospital of Nantes and Centre
- 19 d'Investigation Clinique 1413, Institut National de la Santé et de la Recherche
- Médicale, Nantes, CHU Nantes, Pays de la Loire, Nantes, France 20
- 21 <sup>6</sup> Service de Bactériologie, CHU Nantes, Nantes, France
- 22 <sup>7</sup> INSERM, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Nantes Université, Nantes, France. 23
- 24 <sup>8</sup> Institut Pasteur, Conservatoire National des Arts et Métiers, Unité PACRI, Paris, France 25
- 26 \*Equal contribution
- 27 <sup>†</sup>Members are listed in the Acknowledgements section
- 28 Running title: Exploring multidrug resistance E. coli with machine learning
- 29 Abstract word count: 296 words
- 30 Text word count: 3499 words
- 31 Corresponding author: Laura TEMIME, PhD, CNAM, Paris, France
- (laura.temime@lecnam.net). Tel.: +33 153018011. 32
- 33

# 34 Abstract

# 35 Background

36 While associations of antibiotic resistance traits are not random in multidrug-resistant (MDR)

37 bacteria, clinically relevant resistance patterns remain relatively underexplored. This study

38 used machine learning, specifically association-set mining, to explore resistance associations

39 within *E. coli* isolates from community-acquired urinary tract infections (UTIs).

# 40 Methods

41 We analysed antibiograms of community-acquired *E. coli* UTI isolates collected from 2018 to

42 2022 by France's national surveillance system. Association-set mining was applied separately

43 to extended-spectrum beta-lactamase-producing *E. coli* (ESBL-EC) and non-ESBL-EC. MDR

44 patterns that had expected support (reflecting pattern frequency) and conditional lift (reflecting

45 association strength) higher than expected by chance (p-value≤0.05) were used to construct

46 resistance networks, and analysed according to time, age and gender.

# 47 Findings

48 The number of isolates increased from 360 287 in 2018 (10 150 ESBL-EC, 350 137 non-ESBL-49 EC) to 629 017 in 2022 (18 663 ESBL-EC, 610 354 non-ESBL-EC). More MDR patterns were 50 selected in ESBL-EC than non-ESBL-EC (2022: 1770 vs 93 patterns), with higher respective 51 network densities (2022: 0.230 vs 0.074). Fluoroquinolone, third-generation cephalosporin and 52 penicillin resistances were strongly associated in ESBL-EC. The median densities of 53 resistance association networks increased from 2018 to 2022 in both ESBL-EC (0.238 to 54 0.302, p-value=0.06, Pearson test) and non-ESBL-EC (0.074 to 0.100, p-value=0.04). Across 55 all years, median network densities were higher in men than women in both ESBL-EC (2022: 0.305 vs 0.276) and non-ESBL-EC (2022: 0.128 vs 0.094); they were also higher in individuals 56 57 over 65 years old than under 65 in ESBL-EC (2022: 0.289 vs 0.275) and non-ESBL-EC (2022: 58 0.103 vs 0.088).

# 59 Interpretation

60 These findings, which show increasing MDR associations, especially in men and older 61 individuals, highlight the importance of ongoing resistance surveillance to understand the 62 future evolution of resistance patterns.

# 63 Funding

64 This work received funding from the French government through the National Research 65 Agency project COMBINE ANR–22-PAMR-0003.

66 **Keywords:** Machine learning, Community-acquired *E. coli* UTI (urinary tract infection), 67 multiresistance pattern, antibiotic resistance, network analysis

# 69 **Research in context**

# 70 Evidence before this study

71 We searched Pubmed for previously published articles without any date or language 72 restrictions using the search terms (multiresistan\* OR "multidrug-resistan\*") AND ("data 73 mining" OR "machine learning" OR "artificial intelligence") AND (pattern\* OR associat\*). We 74 found three studies that used machine learning to identify multiresistance patterns in various 75 pathogens (chicken-associated Escherichia coli, human-associated Staphylococcus aureus 76 and cattle-associated Salmonella enterica) in the United States. However, to our knowledge, 77 no machine-learning studies to date have explored multiresistance patterns in human-78 associated Enterobacterales, especially within European contexts.

# 79 Added value of this study

80 Our study provided a novel and detailed analysis of multiresistance patterns in community-81 acquired *E. coli* urinary tract infection collected from a French national surveillance system. 82 Our findings confirmed that association-set mining is effective for identifying resistance 83 associations in antibiotic resistance surveillance data. We explored the temporal evolution of 84 resistance associations, gender-specific and age-specific differences, which to our knowledge, 85 had not been previously analysed.

# 86 Implications of all the available evidence

87 Our results suggest a temporal increase of resistance associations in community-acquired *E*.

88 coli UTI and identify key patterns in different subpopulations. In the context of rising antibiotic

89 resistance, optimizing the use of current medications is crucial, as few new antibiotics have

- 90 been developed in the past two decades. With further research, this work could provide insight
- 91 for targeted antibiotic stewardship strategies.
- 92

### Introduction 93

94 Antimicrobial-resistance (AMR) is an increasing public health issue, notably due to the 95 extensive use of antibiotics and increasing global mobility. Infections caused by multidrug-96 resistant bacteria are challenging to treat, resulting in increased mortality, prolonged hospital 97 stays and higher healthcare costs (1). Initially regarded as a hospital-specific issue, AMR is 98 now recognized as a major problem in community settings and a one-health issue (2). In 2021, 99 AMR-associated infections were directly responsible for approximately 1.14 million deaths 100 globally (3). Multiple studies forecast an increase in resistance to available antibiotics, which 101 could cause >8 million deaths in 2050 (3). The global burden of AMR is driven by a few leading 102 microorganisms, among which resistant E. coli infections caused the highest number of deaths 103 in 2019 (4).

104 Multidrug resistance (MDR) does not result from individual drug resistances occurring together 105 by chance, as documented in multiple bacteria (5). Beyond selection pressure, several 106 biological mechanisms are known to contribute to MDR emergence, including horizontal gene 107 transfer (6), non-specific mechanisms like efflux pumps and specific mechanisms like beta-108 lactamases (5).

109 Here, we use association-set mining, a method that has proven effective in identifying patterns 110 of antibiotic resistance traits in chicken-associated Escherichia coli, human-associated 111 Staphylococcus aureus and cattle-associated Salmonella enterica (7-9), to identify 112 multiresistance patterns in community-acquired E. coli urinary tract infections (UTIs) collected by the French national surveillance system of antibiotic resistance. We create graphical 113 114 networks from the patterns detected by the algorithm in order to highlight resistance 115 associations of interest. By comprehensively studying MDR patterns, we aim to better 116 understand their evolution over time and potential differences across subpopulations.

# 118 Methods

# 119 Data source

120 This study used retrospective data collected via PRIMO (Surveillance and Prevention of 121 Antibiotic Resistance in Primary Care and Nursing Homes), a French nationwide surveillance 122 system of clinical laboratories participating on a voluntary basis (742 laboratories in 2018, 1773 123 laboratories in 2022) (10). Data included antibiotic susceptibility testing (AST) results, patient's 124 age, gender, and administrative region. We restricted the analyses to AST collected from *E.* 125 *coli* UTI collected in community laboratories between January 1<sup>st</sup>, 2018 and December 31<sup>st</sup>, 126 2022.

127 AST and Extended-spectrum beta-lactamases (ESBL) testing were carried out and assessed 128 according to the recommendations of the AST committee of the French Microbiology Society 129 (11). Each isolate was tested against 3 to 35 antibiotics and categorized in a Susceptible, 130 Susceptible to increased exposure or Resistant format. For this analysis, Susceptible to 131 increased exposure and Resistant were grouped as Resistant. We excluded antibiotics that 132 were tested on less than 10% of isolates on average across all years, and included a single 133 representative antibiotic when several antibiotics had similar resistance patterns. This process 134 resulted in the inclusion of 27 antibiotics (Supplementary Table 1). Carbapenemase-producing 135 isolates were excluded from the analysis as their low frequency did not allow for a robust 136 analysis of their specific multiresistance patterns. To avoid duplicates, when multiple isolates 137 with the same susceptibility pattern were collected from the same individual (same date of birth 138 and sex) within a single clinical laboratory, only the first isolate in the dataset was included.

Because the analysis was performed using anonymized surveillance data, ethical consent was
 not required according to the French Data Protection Act. The dataset was accredited by the
 French National Data Protection Commission (CNIL 1,685,003), and the fully anonymized data

142 waiver for informed consent of study participants was applied.

# 143 Data stratification

We classified isolates into two phenotype categories: ESBL-producing *E. coli* (ESBL-EC), either alone or combined with another phenotype, and non-ESBL-producing *E. coli* (non-ESBL-EC). We conducted analyses separately for each year and phenotype dataset. To explore potential gender- and age-based differences in multiresistance patterns, we also conducted

stratified analyses by sex and separate analyses for individuals aged under and over 65.

# 149 **Testing the independence of individual resistances**

150 We first assessed the independence of individual resistances (8). In the following, H0 refers to 151 the hypothesis that assumes all resistance traits to antibiotics are mutually independent. We 152 simulated 100 datasets under H0, that matched the observed datasets in size, resistance 153 prevalence, and positions of missing AST results. Resistance traits were generated as 154 independent binomial random variables (n = number of isolates tested; p = resistance 155 prevalence). To evaluate the likelihood of the observed MDR prevalence under H0, we 156 compared the distribution of resistance counts per isolate between observed and simulated 157 data using a Kolmogorov-Smirnov test.

# 158 Multiresistance patterns identification

We identified MDR patterns from our datasets using association-set mining with the *Apriori* algorithm, as previously proposed by Cazer et al. (8,12). Briefly, we first explored the datasets to select all patterns present with a given frequency, setting the required initial minimum frequency at 0.01 for ESBL-EC and 0.001 for non-ESBL-EC. In a second step, we pruned

163 patterns for which two important metrics, expected support (eSup) and conditional lift (cLift), 164 were significantly lower than expected by chance. To do this, we determined the 5<sup>th</sup> percentile 165 of eSup and cLift under the resistance independence hypothesis H0 using the previously 166 described 100 datasets simulated under H0. eSup measures the pattern frequency within the 167 dataset, while cLift assesses the frequency of a pattern relative to its expected frequency under 168 the assumption that resistance to antibiotics within the pattern are independent. More details on multiresistance pattern identification and accounting for missing data are provided in 169

170 Supplementary Text 2.

### 171 Construction and analysis of resistance associations networks

172 We decomposed the MDR patterns remaining after pruning into pairwise associations, and 173 built resistance association networks, where nodes represent antibiotics and edges represent 174 resistance associations between two antibiotics.

175 For each reconstructed network, we computed network density. Confidence intervals were 176 estimated using: (i) for 2018, 10 datasets generated by a bootstrap procedure of the original 177 dataset, (ii) for 2019 to 2022, 10 random subsamples of the original datasets, each created to 178 match the size of the 2018 dataset. We calculated the 95% confidence intervals from the 2.5<sup>th</sup> 179 and the 97.5<sup>th</sup> percentiles of the results. Time changes in network density were assessed using 180 these constant-size yearly samples, and a Pearson trend test.

181 Networks were also compared between men and women, and individuals under or over 65 182 years old. Similarly to between-year comparisons, we generated 10 random subsamples of 183 the women's (resp. over-65) dataset to match the size of the men's (resp under-65) dataset 184 and computed 95% confidence intervals from either bootstrapped data or these subsamples.

#### 185 Sensitivity analysis

186 The regional contributions to the national dataset varied over the years. To investigate the 187 impact of these variations on our results, we created a dataset where the number of isolates 188 from each region was proportional to its population (details in Supplementary Text 3), and 189 replicated our analyses using this dataset.

190 All analyses were performed in R 4.3.2, notably using the package "arules" for association-set 191 mining (Hahsler et al., 2018).

# 193 **Results**

# 194 Data description

195 The number of isolates increased over time, from 360 287 in 2018 to 628 993 in 2022 (Table

196 1; p-value=0.01, Pearson trend test). The proportion of ESBL isolates was comprised between

197 2.8% and 3.0%, with no increasing or decreasing trend across the years (p-value=0.79).
 198 Throughout all years, between 84.0% and 84.5% of isolates came from women. The mean age

198 Throughout all years, between 84.0% and 84.5% of isolates came from women. The mean age 199 ranged from 58 to 60. The isolates came from all regions of metropolitan France, with varying

200 proportions across the years (Figure S1).

|                       | 2018    | 2019    | 2020    | 2021    | 2022    |
|-----------------------|---------|---------|---------|---------|---------|
| Number of<br>isolates | 360 287 | 450 820 | 450 135 | 571 126 | 628 993 |
| ESBL                  | 10 150  | 13 559  | 13 265  | 16 006  | 18 663  |
|                       | (2.8%)  | (3.0%)  | (2.9%)  | (2.8%)  | (3.0%)  |
| Non-ESBL              | 350 137 | 437 261 | 436 870 | 555 120 | 610 330 |
|                       | (97.2%) | (97.0%) | (97.1%) | (97.2%) | (97.0%) |
| Women                 | 276 220 | 356 002 | 361 758 | 457 789 | 520 081 |
|                       | (84.5%) | (84.4%) | (84.0%) | (84.3%) | (84.1%) |
| Men                   | 50 706  | 66 000  | 68 730  | 85 444  | 98 055  |
|                       | (15.5%) | (15.6%) | (16.0%) | (16.7%) | (15.9%) |
| Mean age              | 58      | 59      | 59      | 60      | 60      |

# Table 1: Summary of PRIMO datasets for *E. coli* UTI samples from 2018 to 2022.

202

# 203 Individual antibiotic resistance prevalence in ESBL-EC and non-ESBL-EC

204 Regarding penicillins, nearly all ESBL isolates were resistant to ampicillin, amoxicillin and 205 ticarcillin (Figure 1A). Most ESBL isolates were resistant to second- and third-generation 206 cephalosporins, including cefuroxime (100%, 1 535/1 535 tested in 2022), ceftriaxone (99.6%, 207 18 592/18 663 tested) and cefotaxime (99.6%, 18 592/18 663 tested). For fluoroquinolones, 208 between 70% and 85% of isolates were resistant to ciprofloxacin, levofloxacin, norfloxacin and 209 ofloxacin. However, most ESBL isolates were sensitive to first-line antibiotics including 210 fosfomycin (4.9%, 834/17 180 tested), nitrofurantoin (1.9%, 348/18 259 tested), mecillinam 211 (10.8%, 1 800/16 684 tested) and cefoxitin (11.1%, 2035/18 380 tested).

212 Non-ESBL isolates were often resistant to penicillins including ampicillin (41.8%, 203 547/486 592 tested), amoxicillin (42.3%, 251 107/593 743 tested) and ticarcillin (40.9%, 223 404/546 213 214 477 tested) (Figure 1B). Less than 1% of isolates were resistant to third generation 215 cephalosporins including ceftazidime, cefixime, ceftriaxone and cefotaxime. For 216 fluoroguinolones, between 5% and 15% of isolates were resistant to ciprofloxacin, levofloxacin, 217 norfloxacin and ofloxacin. Similar individual antibiotic resistance prevalences were found from 218 2018 to 2021 (Figure S2).



219

Figure 1: Resistance prevalence and AST frequency for all antibiotics in 2022 in (A) ESBL-EC and (B) non-ESBL-EC. See supplementary Table 1 for a complete list of antibiotics with their full name.

223

### 224 Independence of individual resistance traits

225 The observed distribution of the number of resistances per isolate significantly differed from 226 the simulated distribution under the hypothesis of independence (p-value = 6.81.10<sup>-3</sup>, 227 Kolmogorov-Smirnov test), suggesting that individual resistances were not independent 228 (Figure 2). In the observed dataset, 39% of isolates were pansusceptible, compared to 9% in 229 the simulated dataset. Similar results were obtained when comparing the distributions of the 230 number of resistances per isolate in observed and simulated data from 2018 to 2021 (Figure 231 S3). We also compared the distributions separately for ESBL-EC and non-ESBL-EC from 2018 232 to 2022 (Figure S4), underlining that the difference was mostly driven by non-ESBL-EC.





Figure 2: Distribution of the number of resistances per isolate in 2022 for all isolates.
 The red line represents the observed dataset, and the grey lines represent the simulated datasets.

237

# 238 Multiresistance pattern selection

For ESBL-EC, the *Apriori* algorithm initially identified 52 824 patterns in 2018 and 123 116 patterns in 2022, with an increasing trend over the years (p-value=0.01, Pearson test) (Table 2). For non-ESBL-EC, the algorithm initially generated 2 529 patterns in 2018 and 4 515 patterns in 2022, with a non-significant increasing trend (p-value=0.06, Pearson test).

For 2022, the eSup cut-off values were 0.271 for ESBL-EC isolates and 0.034 for non-ESBL-EC, meaning that a pattern was selected if it appeared in at least 27.1% of ESBL-EC or 3.4% of non-ESBL-EC. This value was relatively stable over time for both ESBL (range: 23.6-27.1%, p-value=0.22, Mann-Kendall test) and non-ESBL-EC (range: 2.9-3.4%, p-value=0.13, Mann-Kendall test).

The cLift cut-off value for ESBL-EC and non-ESBL-EC was respectively 1.058 and 1.041 in 2022, meaning that a pattern was selected if it was 5.8% (resp. 4.1%) more frequent than expected by chance under the assumption of resistance independence in ESBL-EC (resp. non-ESBL-EC). These cut-offs were again relatively stable over time for both ESBL-EC (pvalue=0.46, Mann-Kendall test) and non-ESBL-EC (p-value=0.09, Mann-Kendall test).

The pruning step selected respectively 1 770 (1.43% of patterns) and 93 (2.06%) patterns for ESBL-EC and non-ESBL-EC in 2022. The number of selected patterns had an increasing trend from 2018 to 2022 for both ESBL-EC (p-value=0.03, Pearson test) and non-ESBL-EC (pvalue=0.05, Pearson test).

257

# Table 2: Number of multiresistance patterns selected by association-set mining for each year and phenotype subset. For example, in 2018 ESBL-EC, 52 736 patterns were identified.

260 Cut-off values were set at eSup  $\ge 0.257$  and cLift  $\ge 1.076$ , meaning that a pattern was retained 261 if it appeared in at least 25.7% of isolates and occurred 7.6% more frequently than expected 262 under the assumption of independence between resistance traits. After pruning, 483 patterns 263 were selected.

| Phenotype | Year | Number of<br>patterns | eSup<br>cut-off | cLift<br>cut-off | Number of<br>patterns |
|-----------|------|-----------------------|-----------------|------------------|-----------------------|
|           |      | Initially             | value           | value            | Selected              |

|          |      | generated<br>by the<br>Apriori<br>algorithm |       |       | after<br>pruning |
|----------|------|---|-------|-------|------------------|
| ESBL     | 2018 | 52 736                                      | 0.257 | 1.076 | 483              |
|          | 2019 | 86 454                                      | 0.236 | 1.070 | 1 234            |
|          | 2020 | 106 625                                     | 0.242 | 1.073 | 1 268            |
|          | 2021 | 115 425                                     | 0.262 | 1.065 | 1 921            |
|          | 2022 | 123 116                                     | 0.271 | 1.058 | 1 770            |
| Non-ESBL | 2018 | 2 527                                       | 0.030 | 1.056 | 59               |
|          | 2019 | 3 936                                       | 0.029 | 1.051 | 82               |
|          | 2020 | 3 756                                       | 0.030 | 1.052 | 75               |
|          | 2021 | 4 945                                       | 0.031 | 1.045 | 88               |
|          | 2022 | 4 502                                       | 0.034 | 1.041 | 93               |

264

265

#### 266 Networks of resistance associations

#### 267 Resistance associations networks have higher density for ESBL-EC

268 Resistance associations networks were much denser in ESBL-EC than non-ESBL-EC, with 269 densities of respectively 0.301 and 0.100 in 2022 (Figure 3). As expected, resistance associations in ESBL-EC involved mainly penicillins, third-generation cephalosporins and 270 271 fluoroquinolones. In non-ESBL-EC, strong resistance associations were found between 272 penicillins, combinations of penicillin and beta-lactamase inhibitor and guinolones. Regarding 273 first-line antibiotics, almost no significant association involving nitrofurantoin, fosfomycin, mecillinam nor any aminoglycoside was found in both ESBL- and non-ESBL-EC. However, 274 275 trimethoprim/sulfamethoxazole was associated with third-generation cephalosporins in ESBL-276 EC and with penicillins in non-ESBL-EC.



279 Figure 3: Networks generated from ESBL-EC (A) and non-ESBL-EC (B) in 2022. Patterns were decomposed into nodes (antibiotics) and edges. Nodes are colored with a pie chart; the 280 281 grey part is the proportion of isolates not tested for this antibiotic, the white part is the proportion 282 of isolates susceptible to this antibiotic and the colored part is the proportion of isolates resistant to this antibiotic. Node color reflects the antibiotic class. Edge color is darker with a 283 284 high cLift value, meaning that the two antibiotics are substantially more frequently together in 285 a resistance pattern than expected if resistance traits were independent. Edge width is higher 286 with a high eSup value, meaning that the two antibiotics are frequently found together in a 287 resistance pattern. See supplementary Table 1 for a complete list of antibiotics with their full 288 name.

289

278

### 290 Network density increases over time for both ESBL-EC and non-ESBL-EC

291 Network density increased over time, from 0.238 [0.234; 0.249] in 2018 to 0.301 [0.294; 0.302] in 2022 for ESBL-EC (p-value=0.06, Pearson test), and from 0.074 [0.074; 0.074] in 2018 to 292 293 0.100 [0.100; 0.103] in 2022 for non-ESBL-EC (p-value=0.04, Pearson test) (Figure 4).

medRxiv preprint doi: https://doi.org/10.1101/2025.02.05.25321745; this version posted February 8, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in





295 Figure 4: Networks of resistance associations from 2018 to 2022. Median density and 95% 296 confidence interval calculated using: (i) for 2018, 10 bootstrapped datasets, (ii) for 2019 to 297 2022, 10 subsamples randomly drawn to match the size of the 2018 dataset. See 298 supplementary Table 1 for a complete list of antibiotics with their full name.

299

294

#### 300 Network density is higher in 65+ years old

301 For non-ESBL-EC, resistance associations networks were denser in individuals aged 65 and 302 over than in individuals under 65, with median densities of respectively 0.103 [0.103; 0.105] 303 and 0.088 [0.088; 0.091] in 2022 (Figure 5B). For ESBL-EC, the median network density was 304 not significantly different between 65+ years old, at 0.289 [0.280; 0.301], and -65 years old, at 305 0.275 [0.261; 0.294]. The ESBL-EC networks of 65+ individuals mainly involved additional associations of cefuroxime with penicillins (amoxicillin, ampicillin), third and fourth generation 306 307 cephalosporin (cefotaxime, cefepime) and fluoroquinolones (ciprofloxacin, levofloxacin, 308 norfloxacin) (Figure 5A). Similar results were found when analysing data from 2018 to 2021 309 (Figure S5).



### 310

311 Figure 5: (A) Networks of resistance associations for individuals under 65 and 312 individuals 65 and over in 2022. (B) Barplots of median network density for both age 313 groups. Error bars indicate confidence interval: for individuals over 65, calculated using 10 314 subsamples randomly generated at the size of the dataset of individuals under 65; for 315 individuals under 65, calculated using 10 bootstrapped datasets from the complete dataset of individuals under 65. See supplementary Table 1 for a complete list of antibiotics with their full 316 317 name.

318

#### 319 Network density is higher in men

320 In 2022 for ESBL-EC, network density was higher in men than in women, with respective 321 medians of 0.305 [0.291; 0.322] and 0.271 [0.266; 0.276] (Figure 6B). The same result was 322 observed in non-ESBL-EC, with median densities of 0.128 [0.125; 0.133] and 0.094 [0.090; 323 0.096] for men and women respectively. The ESBL-EC networks of men mainly involved 324 additional associations of cefuroxime with penicillins (amoxicillin, ampicillin), third and fourth 325 generation cephalosporin (cefotaxime, cefepime) and fluoroquinolones (ciprofloxacin, levofloxacin, norfloxacin) (Figure 6A). Similar results were found when analysing data from 326 327 2018 to 2021 (Figure S6).



328

329 Figure 6: (A) Networks of resistance associations for men and women in 2022. (B) 330 Barplots of the median network density for men and women. Error bars indicate confidence intervals: for women, calculated using 10 datasets generated at the size of the 331 332 men's dataset; for men, calculated using 10 bootstrapped datasets from the complete men's 333 dataset. See supplementary Table 1 for a complete list of antibiotics with their full name.

334

#### 335 Sensitivity analysis

336 Figure S7 depicts resistance association networks from 2019 to 2022, obtained with resampled 337 datasets to ensure that the relative contribution of each region is constant over time and 338 proportional to its population. As in the main analysis, networks reconstructed for ESBL-EC 339 isolates were much denser than for non-ESBL-EC. For ESBL-EC, a significant increase in 340 density was again observed over time, from 0.240 to 0.300 (p-value=0.004, Pearson test), 341 although this was not the case any more for non-ESBL-EC.

# 343 **Discussion**

In this study we identified resistance associations in community-acquired UTI *E. coli* isolates, using a large French surveillance database. Across all years, and as expected, ESBL-EC showed a higher number of resistance associations, particularly involving penicillins, fluoroquinolones and third-generation cephalosporins. In both ESBL and non-ESBL-EC, the number of resistance associations increased from 2018 to 2022, and men and individuals aged 65 and over showed more resistance associations across all years.

We compared the observed distribution of the number of resistances per isolate with a simulated dataset assuming the hypothesis of mutual independence of resistance traits (8) and found significant differences. This finding aligns with Chang et al., 2015, which reported that MDR occurred at frequencies inconsistent with the hypothesis of mutual independence of resistance traits for multiple bacteria including *E. coli* (5). It provides further evidence for biological or genetic mechanisms favouring the co-occurrence of multiple resistance traits in *E. coli*.

357 Resistance rates were generally low for first-line antibiotics recommended in France for 358 community-acquired UTIs, such as fosfomycin, pivmecillinam or nitrofurantoin (13). Analysis 359 of ESBL-EC resistance associations networks highlighted major associations between 360 penicillins (+/- inhibitors), cephalosporins, fluoroquinolones and cotrimoxazole. This pattern 361 may correspond to CTX-M, the most prevalent ESBL in E. coli, as well as TEM or SHV 362 enzymes, which all hydrolyse penicillins and cephalosporins. CTX-M are mostly susceptible to 363 piperacillin-tazobactam (~80–90%), while this is more variable in TEM/SHV. They are both 364 highly resistant to fluoroquinolones (80-90%), and moderately resistant (~50%) to 365 cotrimoxazole. Although the mechanisms of resistance to beta-lactams and fluoroquinolones 366 are distinct, fluoroquinolone resistance genes (e.g., qnr or aac(6')-lb-cr) are present on mobile 367 genetic elements that also carry beta-lactam resistance genes, which allows multiple 368 resistances to be transmitted jointly (14). Association-set mining may represent an efficient 369 approach to better understand the dynamics of E. coli multiresistance patterns and make 370 hypothesis regarding the underlying genetic evolutions, to be confirmed by whole genome 371 sequencing analysis.

Using association-set mining, we found that the number of resistance associations increased 372 373 from 2018 to 2022 in both ESBL-EC and non-ESBL-EC. Despite this overall increasing trend, 374 a temporary decrease was observed in 2020, consistently with the observed reduction in MDR 375 E. coli during the Covid-19 pandemic in France (15). We explored the impact of spatial 376 resistance epidemiology on our findings through a sensitivity analysis using datasets where 377 the number of isolates from each region was proportional to its population. This approach 378 confirmed the nationwide increase of resistance associations within community-acquired 379 ESBL-EC UTIs. However, in this sensitivity analysis, the increase in non-ESBL-EC isolates 380 disappeared. Consequently, the changes in regional relative contributions may have played a 381 role in the temporal increase of the number of resistance associations we observed in non-382 ESBL-EC isolates. In particular, the contribution of several densely-populated and 383 internationally-connected French regions, including Ile-de-France (Paris area), increased over 384 time. Isolates from these regions may present more resistance associations.

During 2018-2022, the global consumption of antibiotics in primary care decreased in France from 22.9 to 21.6 defined daily doses (DDD) per 10,000 inhabitant per day. This trend was observed for large-spectrum penicillins, cephalosporins and quinolones, but not for associations of penicillins, sulphonamides and trimethoprim which remained stable. In this context, the increasingly dense MDR patterns we observe among community *E. coli* may be driven not only by antibiotic use but also by other multiple human, animal, and environmentalfactors (16).

392 Isolates coming from men and individuals older than 65 had more resistance associations, 393 even after adjusting for different sample sizes. This finding is consistent with multiple studies 394 showing that older individuals are particularly exposed to MDR bacteria notably because of 395 immunosenescence, frequent multiple chronic comorbidities and the associated requirement 396 for care. They are more frequently exposed to hospitals and other healthcare facilities, 397 increasing their contact with resistant bacteria (17,18). In contrast, limited data is available 398 regarding gender-specific differences in MDR, although some studies suggested that men 399 have more risks than women to be infected with resistant bacteria (19-21). In our study, men-400 specific networks had additional associations involving cefuroxime. In hospital settings, 401 cefuroxime is routinely used as surgical prophylaxis to reduce the risk of postoperative 402 infections, particularly in prostate resection, a frequent procedure in older men (22). Moreover, 403 UTIs in men are more commonly associated with structural abnormalities like renal stones and 404 malignancies, which can complicate the treatment, lead to increased antibiotic use and 405 contribute to the development of resistance (23). This could partially explain the additional 406 associations.

407 Our study is subject to certain limitations that should be taken into account.

408 First, the size of the PRIMO datasets generally increased every year, notably due to the 409 increase of the scope of the PRIMO mission. However, the 2020 dataset was slightly smaller 410 than the 2019 one (450 135 vs. 450 820 isolates). This could be partially explained by the 411 COVID-19 pandemic which disrupted healthcare systems and microbiological surveillance 412 practices in 2020. Community clinical laboratories prioritized COVID-19 management, 413 potentially reducing their capacity to collect and record AST (24). While network size is known 414 to impact its density (25), in our analyses, we accounted for varying dataset sizes by randomly 415 drawing subsamples at the size of the 2018 dataset.

Second, the PRIMO surveillance system contained isolates that were collected in community clinical laboratories; however, we cannot be certain that it was representative of the total community-acquired *E. coli* UTI in France between 2018 and 2022. Some isolates could have been acquired in healthcare settings, especially for older individuals who are frequently hospitalized. Moreover, while we were unable to collect clinical information, some *E. coli* were potentially isolated from asymptomatic bacteriuria of colonised patients.

Third, our results are valid for *E. coli* isolates only, and not for other Enterobacterales, potentially limiting their generalizability. We chose to focus the study on *E. coli* as it represented 85.0% of all isolates in the dataset.

425 Fourth, in the PRIMO database, some antibiotics were tested on a very small number of 426 isolates. To minimize bias, we included only antibiotics tested on at least 10% of isolates 427 across all datasets. We found stable results for most antibiotics over time. However, this 428 limitation may explain the changing results regarding ampicillin from 2018 to 2019. In 2018, 429 ampicillin was tested on only 2% of isolates, which likely prevented the algorithm from 430 identifying significant associations involving this antibiotic. By 2019, ampicillin was tested on 431 more isolates, allowing the algorithm to detected such associations. Moreover, the antibiotics 432 tested were determined by the laboratories, and might not align with hospital practices, while 433 consistent with practices in outpatient care.

Fifth, the *Apriori* algorithm is a highly efficient method supported by multiple studies (7–9). However, combining multiple data mining approaches, as recently suggested (9), could have enhanced our understanding of MDR. In addition, *Apriori* generates numerous patterns,

437 requiring careful pruning with appropriate quality measures and cut-off values. While many 438 studies rely solely on support (26), this would have favoured frequent resistance patterns, such 439 as those involving amoxicillin, while overlooking rarer but significant associations. We therefore 440 chose lift as a robust complementary metric (7); however, numerous other metrics or metric 441 combinations could be proposed (27,28), potentially yielding slightly different results. Missing 442 data may also have influenced Apriori results by altering resistance prevalence distributions 443 and associations (29), although this was addressed by the use of adapted quality measures 444 (eSup and cLift) (30). Finally, cut-off values also influence pattern selection (26). Our 445 percentile-based approach led us to exclude patterns with a lift below 1, which could have 446 highlighted MDR patterns occurring less frequently than expected.

447 Despite these limitations, our study provided a novel and detailed analysis of multiresistance 448 patterns in community-acquired E. coli UTI collected from a French national surveillance 449 system. We explored the temporal evolution of resistance associations, gender-specific and 450 age-specific differences, which to our knowledge, had not been previously analysed. Our 451 findings confirmed that this method is effective for identifying resistance associations in 452 antibiotic resistance surveillance data. With further research, this work could provide insights 453 for antibiotic stewardship strategies in alignment with known resistance associations in 454 community-acquired E. coli UTIs. In the context of rising antibiotic resistance, optimizing the 455 use of current medications is crucial, as few new antibiotics have been developed in the past 456 two decades (31).

457 Future research could use other machine learning approaches to further analyse the PRIMO 458 datasets and get a deeper understanding of resistance associations. Moreover, it would be 459 interesting to examine the evolution of resistance associations in future years. In addition, 460 extending our approach to other pathogens beyond E. coli could offer a broader perspective 461 on multiresistance dynamics. Finally, future work could investigate the potential linkage 462 between these phenotypic resistance associations and genetic co-resistance mechanisms.

463

### List of abbreviations 464

- 465 AMR: Antimicrobial-resistant
- 466 AST: Antibiotic susceptibility testing
- 467 cLift: conditional lift
- 468 DDD: defined daily dose
- 469 ESBL-EC: Extended-spectrum beta-lactamase producing E. coli
- 470 eSup: expected support
- 471 MDR: multidrug-resistant
- 472 UTI: urinary tract infection

# 474 **Declarations**

### 475 Ethics approval and consent to participate

- 476 Because the analysis was performed using anonymized surveillance data, ethical consent
- 477 was not required according to the French Data Protection Act. The dataset was accredited by
- 478 the French National Data Protection Commission (CNIL 1,685,003), and the fully
- anonymized data waiver for informed consent of study participants was applied.

### 480 Availability of data and materials

- 481 All code used in the analysis are available in the following GitHub repository:
- 482 <u>https://github.com/elisehodbert/exploring MDR patterns</u>

### 483 Competing interest

- 484 Dr Birgand reported receiving grants from Santé Publique France during the conduct of the 485 study. No other disclosure was reported.
- 486 Disclaimer: The views expressed are those of the authors and not necessarily those of Santé487 Publique France or the ANR.

### 488 Funding

- This work received funding from the French government through the National Research
  Agency project COMBINE ANR –22-PAMR-0003.
- 491 Role of the Funder/Sponsor: The sponsors had no role in the design and conduct of
- the study; collection, management, analysis, and interpretation of the data;
- 493 preparation, review, or approval of the manuscript; and decision to submit the
- 494 manuscript for publication.

# 495 Authors' contributions

- 496 Dr Birgand had full access to all of the data in the study and takes responsibility for the 497 integrity of the data and the accuracy of the data analysis.
- 498 Concept and design: Hodbert, Lemenand, Temime, Birgand.
- 499 Acquisition, analysis, or interpretation of data: Hodbert, Thibaut, Coeffic, Lemenand,
- 500 Temime, Boutoille, Corvec, Birgand.
- 501 Drafting of the manuscript: Hodbert, Birgand, Temime.
- 502 Critical revision of the manuscript for important intellectual content: Hodbert, Lemenand,
- 503 Corvec, Boutoille, Birgand, Temime.
- 504 Statistical analysis: Hodbert, Coeffic, Temime
- 505 Obtained funding: Birgand, Temime.
- 506 Administrative, technical, or material support: Birgand, Temime.
- 507 Supervision: Temime, Lemenand, Birgand.

### 508 Acknowledgements

- 509 French clinical laboratories nationwide network: A. Vrain, LABOUEST, Ancenis ; P.
- 510 Andorin, BIOLARIS, Laval ; J. Besson, BIOLIANCE, Nantes ; F. Maillet, BIOLOIRE, Nantes ;
- 511 G. de Gastines, BIORYLIS, La Roche sur Yon ; P.-Y. Léonard, LABORIZON MAINE ANJOU,
- 512 Le Mans ; M. Guery, SEVRE BIOLOGIE, Les Herbiers ; V. Plong, ACTIV'BIOLAB, Challans ;
- 513 N. Le Moing, RESEAUBIO, La Chapelle sur Erdre ; F. Kerdavid, ALLIANCE ANABIO,
- 514 Melesse ; A.-S. Reinhard, BIOCELIANDE, Montauban de Bretagne ; S. Gillard, BIOLOR,

- 515 Lorient ; B. Guesnon, BIORANCE, Saint Malo ; B. Gestin, LABAZUR, Chateaulin ; H. 516 Banctel, SBL BIO, Saint Brieuc ; D. Laforest, BIOCENTRE, Coutances ; E. Pradier, CARMES, Caen ; S. Arsene, CERBALLIANCE NORMANDIE, Lisieux ; A. Holstein, ABO +, 517 518 Tours ; D. Bouvet, BIO MEDI QUAL Centre, Vierzon ; B. Dubet, LBM DUBET, Neuville aux 519 bois; C. Laudignon, MLAB, Saran; E. Jobert, MIRIALIS, Annecy; R. Gebeile, DYNABIO, 520 Lyon ; S. Poyet, DYOMEDEA, Lyon ; G. Deleglise, GENBIO, Clermont Ferrand ; N. 521 Lecordier, ANALYSIS 88, Epinal; S. Fougnot, ATOUTBIO, Nancy; E. Grandsire, DYNALAB, 522 Romilly sur Seine ; J.-P. Rault, ESPACEBIO, Metz ; G. Defrance, BIOFUTUR, L'isle Adam ; 523 J Cadenet, BIOVSM, Torcy ; L Libier, AX BIO OCEAN, Bayonne ; A Touzalin, BIO17, La 524 Rochelle ; A Allery, BIO86, Poitiers ; H Valade, BIOFFICE, Bordeaux ; G. Payro, 525 CERBALLIANCE-CHARENTE, Saintes; D. Boraud, EXALAB Groupe LABEXA, Le Haillan; 526 E. Parisi, VIALLE, Bastia ; F. Alluin, 2A2B, Porto Vecchio ; J. Bayette, LABOSUD, 527 Montpellier ; M.-F. Aran, BIOPOLE66, Perpignan ; P. Stevenin, BIOAXIOME, Avignon ; A. 528 François, BIOESTEREL, Mandelieu-la-Napoule ; G. Gay, LABOSUD PROVENCE, Marseille 529 ; O. Duquesnoy, BIOPATH, Dunkergue ; V. Sainte Rose, BIOLAB MARTINIQUE, Fort de 530 France ; F. Dos Santos, BIOSANTE, Schoelcher. F. Artur, BIOCEANE, Le Havre. E. 531 Mbenga, BIOLAB, Beaune ; A. Desjardins, EVORIAL, Nevers ; M.-C. Paolini, BDCBM5, 532 Besançon ; P. Marchenay, LPA18, Vesoul.
- 533 Group Information: A complete list of the members of the French Clinical Laboratories 534 Nationwide Network appears in Supplement.
- 535 Additional Contributions: Anne Berger-Carbonne, MD, Laetita Gambotti, and Sylvie 536 Maugat, MSc (from Santé Publique France), supported the data. These individuals were not 537 compensated for their contributions.
- 538

# 540 **References**

- Cosgrove SE. The Relationship between Antimicrobial Resistance and Patient Outcomes: Mortality, Length of Hospital Stay, and Health Care Costs. Clin Infect Dis. 15 janv 2006;42(Supplement 2):S82-9.
- Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al.
   Understanding the mechanisms and drivers of antimicrobial resistance. The Lancet. 9 janv
   2016;387(10014):176-87.
- 3. Naghavi M, Vollset SE, Ikuta KS, Swetschinski LR, Gray AP, Wool EE, et al. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. The Lancet [Internet]. 16 sept 2024 [cité 23 sept 2024];0(0). Disponible sur: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext?dgcid=twitter\_organic\_gbd24\_lancet
- 4. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al. Global
  burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 12
  févr 2022;399(10325):629-55.
- 5. Chang HH, Cohen T, Grad YH, Hanage WP, O'Brien TF, Lipsitch M. Origin and
  proliferation of multiple-drug resistance in bacterial pathogens. Microbiol Mol Biol Rev
  MMBR. mars 2015;79(1):101-16.
- 558 6. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL.
  559 Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving 560 crisis of global dimensions. Clin Microbiol Rev. oct 2012;25(4):682-707.
- 561 7. Cazer CL, Al-Mamun MA, Kaniyamattam K, Love WJ, Booth JG, Lanzas C, et al. Shared
  562 Multidrug Resistance Patterns in Chicken-Associated Escherichia coli Identified by
  563 Association Rule Mining. Front Microbiol [Internet]. 2019 [cité 2 oct 2023];10. Disponible
  564 sur: https://www.frontiersin.org/articles/10.3389/fmicb.2019.00687
- 8. Cazer CL, Westblade LF, Simon MS, Magleby R, Castanheira M, Booth JG, et al. Analysis
  of Multidrug Resistance in Staphylococcus aureus with a Machine Learning-Generated
  Antibiogram. Antimicrob Agents Chemother. 18 mars 2021;65(4):10.1128/aac.02132-20.
- 568 9. Mosaddegh A, Angel CC, Craig M, Cummings KJ, Cazer CL. An exploration of descriptive
   569 machine learning approaches for antimicrobial resistance: Multidrug resistance patterns in
   570 Salmonella enterica. Prev Vet Med. sept 2024;230:106261.
- Lemenand O, Thibaut-Jovelin S, Coeffic T, Caillon J. PRIMO : Résultats 2022 Surveillance de la résistance bactérienne aux antibiotiques en soins de ville et en Ehpad
  [Internet]. Repias : Réseau de Prévention des Infections Associées aux Soins. 2024 [cité
  20 déc 2024]. Disponible sur: https://www.preventioninfection.fr/actualites/primo-resultats2022-surveillance-de-la-resistance-bacterienne-aux-antibiotiques-en-soins-de-ville-et-enehpad/
- 577 11. Cattoir V. Comité de l'Antibiograme de la Société Française de Microbiologie
  578 [Internet]. Société Française de Microbiologie. 2022 [cité 5 févr 2025]. Disponible sur:
  579 https://www.sfm-microbiologie.org/boutique/\_comite-de-lantibiogramme-de-la-sfm-ca-sfm580 v1-0-juin-2024/
- 581 12. Dongre J, Prajapati GL, Tokekar SV. The role of Apriori algorithm for finding the
   582 association rules in Data mining. In: 2014 International Conference on Issues and

medRxiv preprint doi: https://doi.org/10.1101/2025.02.05.25321745; this version posted February 8, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

- perpetuity. It is made available under a CC-BY-NC 4.0 International license .
- 583 Challenges in Intelligent Computing Techniques (ICICT) [Internet]. Ghaziabad, India:
- 584 IEEE; 2014 [cité 4 juin 2024]. p. 657-60. Disponible sur:
- 585 http://ieeexplore.ieee.org/document/6781357/
- 586 13. Caron F, Galperine T, Flateau C, Azria R, Bonacorsi S, Bruyère F, et al. Practice 587 guidelines for the management of adult community-acquired urinary tract infections. Med 588 Mal Infect. 2018;48(5):327-58.
- 589 Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. Plasmid-Mediated Quinolone 14. 590 Resistance: a Multifaceted Threat. Clin Microbiol Rev. oct 2009;22(4):664-89.
- 591 Lemenand O, Coeffic T, Thibaut S, Cotinat MC, Caillon J, Birgand G. Decreasing 15. 592 proportion of extended-spectrum beta-lactamase among E. coli infections during the 593 COVID-19 pandemic in France. J Infect. 1 déc 2021;83(6):664-70.
- 594 16. Paumier A, Asquier-Khati A, Thibaut S, Coeffic T, Lemenand O, Larramendy S, et al. 595 Assessment of Factors Associated With Community-Acquired Extended-Spectrum β-596 Lactamase-Producing Escherichia coli Urinary Tract Infections in France. JAMA Netw 597 Open. 1 sept 2022;5(9):e2232679.
- 598 Gajdács M, Ábrók M, Lázár A, Burián K. Urinary Tract Infections in Elderly Patients: A 17. 599 10-Year Study on Their Epidemiology and Antibiotic Resistance Based on the WHO 600 Access, Watch, Reserve (AWaRe) Classification. Antibiotics. sept 2021;10(9):1098.
- 601 Theodorakis N, Feretzakis G, Hitas C, Kreouzi M, Kalantzi S, Spyridaki A, et al. 18. 602 Antibiotic Resistance in the Elderly: Mechanisms, Risk Factors, and Solutions. 603 Microorganisms. oct 2024;12(10):1978.
- 604 19. Brandl M, Hoffmann A, Willrich N, Reuss A, Reichert F, Walter J, et al. Bugs That Can 605 Resist Antibiotics but Not Men: Gender-Specific Differences in Notified Infections and 606 Colonisations in Germany, 2010–2019. Microorganisms [Internet]. 2021 [cité 18 nov 2024]:9. Disponible sur: https://consensus.app/papers/bugs-that-resist-antibiotics-607 608 genderspecific-differences-brandl/2b9390f598b05d908488d513c5c4a2b3/
- 609 20. Khanal N, Cortie CH, Story C, Jones S, Mansfield KJ, Miyakis S, et al. Multidrug 610 resistance in urinary E. coli higher in males compared to females. BMC Urol. 18 nov 611 2024;24(1):255.
- 612 21. Costa T, Linhares I, Ferreira R, Neves J, Almeida A. Frequency and Antibiotic 613 Resistance of Bacteria Implicated in Community Urinary Tract Infections in North Aveiro 614 Between 2011 and 2014. Microb Drug Resist. mai 2018;24(4):493-504.
- 615 22. Ferrie B, Scott R. Prophylactic cefuroxime in transurethral resection. Urol Res. 616 2004;12:279-81.
- 617 Wagenlehner FME, Weidner W, Pilatz A, Naber KG. Urinary tract infections and 23. 618 bacterial prostatitis in men. Curr Opin Infect Dis. févr 2014;27(1):97.
- 619 24. Durant TJS, Peaper DR, Ferguson D, Schulz WL. Impact of COVID-19 Pandemic on 620 Laboratory Utilization. J Appl Lab Med. 1 nov 2020;5(6):1194-205.
- 621 Snijders T, Borgatti S. Non-Parametric Standard Errors and Tests for Network 25. 622 Statistics. Connections. janv 1999;22.

- It is made available under a CC-BY-NC 4.0 International license.
- 623 26. Martínez-Ballesteros M, Martínez-Álvarez F, Lora AT, Santos JCR. Selecting the best 624 measures to discover quantitative association rules. Neurocomputing. 2014;126:3-14.
- Datta S, Mali K. Significant Association Rule Mining with High Associability. In: 2021
  5th International Conference on Intelligent Computing and Control Systems (ICICCS)
  [Internet]. 2021 [cité 12 déc 2024]. p. 1159-64. Disponible sur: https://ieeexplore.ieee.org/document/9432237
- Tan PN, Kumar V, Srivastava J. Selecting the right interestingness measure for
  association patterns. In: Proceedings of the eighth ACM SIGKDD international conference
  on Knowledge discovery and data mining [Internet]. New York, NY, USA: Association for
  Computing Machinery; 2002 [cité 28 mars 2024]. p. 32-41. (KDD '02). Disponible sur:
  https://doi.org/10.1145/775047.775053
- 634 29. Brown ML, Kros JF. Data mining and the impact of missing data. Ind Manag Data 635 Syst. 1 janv 2003;103(8):611-21.
- 636 30. Calders T, Goethals B, Mampaey M. Mining itemsets in the presence of missing
  637 values: 22nd ACM Symposium on Applied Computing (SAC 2007). Cho Y, Wainwright RL,
  638 Haddad H, Shin SY, Koo YW, éditeurs. Proc 22nd Annu ACM Symp Appl Comput SAC
  639 2007 11-15 March 2007 Seoul Korea. 2007;404-8.
- 840 31. Renwick MJ, Brogan DM, Mossialos E. A systematic review and critical assessment
  841 of incentive strategies for discovery and development of novel antibiotics. J Antibiot
  842 (Tokyo). févr 2016;69(2):73-88.